# Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

> **NCT05581823** · PHASE1 · COMPLETED · sponsor: **Cerevel Therapeutics, LLC** · enrollment: 16 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Tavapadon
- **DRUG:** Carbamazepine

## Key facts

- **NCT ID:** NCT05581823
- **Lead sponsor:** Cerevel Therapeutics, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-19
- **Primary completion:** 2023-01-27
- **Final completion:** 2023-02-02
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2023-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05581823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05581823, "Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05581823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*